Canada’s Drug Agency is seeking feedback on a national bulk purchasing strategy for prescription drugs and related products.
Under the federal Pharmacare Act, the CDA is convening a panel that will develop advice on a national bulk purchasing strategy and is inviting interested parties to provide input on the proposed advice, particularly on approaches that build upon currently available structures and processes to strengthen collective purchasing power.
Read: Private benefits plan sponsors’ prescription drug costs up 12.9% in 2023: report
“Input from a variety of perspectives is highly valued and the comments we receive will be used to inform a final report that will be submitted to Health Canada, shared with provincial and territorial governments and made publicly available,” said the CDA, in a press release.
The advisory panel’s advice on a national bulk purchasing strategy aims to identify ways to obtain best value for Canadians by improving the collective capacity to purchase and procure pharmaceutical products while considering existing processes to increase overall efficiencies without significant disruptions to the current system.
Feedback will be accepted until Aug. 1.
Read: 73% of employers say rising benefits costs a top issue in 2025: survey